BLSI Boston Life Sciences (MM)

HOPKINTON, Mass., Oct. 31 /PRNewswire-FirstCall/ -- Boston Life Sciences, Inc. (NASDAQ:BLSI) today announced that Peter Savas, Chairman and Chief Executive Officer of Boston Life Sciences, Inc., will be presenting a Company update at the Rodman & Renshaw Annual Healthcare Conference on Monday, November 6 from 4:35pm - 4:55pm EST in the Holmes II room. The conference is being held from November 6-8 at the New York Palace Hotel in New York City, NY. The Boston Life Sciences presentation will be available by webcast. Access to the webcast will be available within the Investor Relations section of the Boston Life Sciences website at http://www.bostonlifesciences.com/. About Boston Life Sciences, Inc. Boston Life Sciences, Inc. (BLSI) is engaged in the research and clinical development of diagnostic and therapeutic products for central nervous system (CNS) disorders. ALTROPANE(R) molecular imaging agent is in Phase III clinical trials for the diagnosis of Parkinsonian Syndrome (PS) and Phase II clinical trials for the diagnosis of Attention Deficit Hyperactivity Disorder (ADHD). The Company's research and pre-clinical CNS programs include Inosine for the treatment of stroke, a DAT blocker for the treatment of Parkinson's disease and a second generation technetium-based molecular imaging agent for PS and ADHD. BLSI's current research collaborations include Harvard Medical School and Children's Hospital Boston. Contact: Sharon Correia -- 508-497-2360 ext 224 Boston Life Sciences, Inc. DATASOURCE: Boston Life Sciences, Inc. CONTACT: Sharon Correia of Boston Life Sciences, Inc., +1-508-497-2360, ext. 224, Web site: http://www.bostonlifesciences.com/

Copyright